RS53468B - Inhibitori met aktivnosti za primenu u cilju povećanja efikasnosti radioterapije - Google Patents
Inhibitori met aktivnosti za primenu u cilju povećanja efikasnosti radioterapijeInfo
- Publication number
- RS53468B RS53468B RS20140404A RSP20140404A RS53468B RS 53468 B RS53468 B RS 53468B RS 20140404 A RS20140404 A RS 20140404A RS P20140404 A RSP20140404 A RS P20140404A RS 53468 B RS53468 B RS 53468B
- Authority
- RS
- Serbia
- Prior art keywords
- met
- inhibitor
- met activity
- nucleotide sequence
- activity
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11158861.2A EP2500036B1 (en) | 2011-03-18 | 2011-03-18 | MET inhibitors for enhancing radiotherapy efficacy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS53468B true RS53468B (sr) | 2014-12-31 |
Family
ID=44260211
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20140404A RS53468B (sr) | 2011-03-18 | 2011-03-18 | Inhibitori met aktivnosti za primenu u cilju povećanja efikasnosti radioterapije |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20120237524A1 (enExample) |
| EP (1) | EP2500036B1 (enExample) |
| JP (1) | JP5671487B2 (enExample) |
| KR (1) | KR101540838B1 (enExample) |
| CN (1) | CN102688491A (enExample) |
| AU (1) | AU2012201303B2 (enExample) |
| BR (1) | BR102012006063B1 (enExample) |
| CA (1) | CA2769991C (enExample) |
| CY (1) | CY1115374T1 (enExample) |
| DK (1) | DK2500036T3 (enExample) |
| EA (1) | EA028590B1 (enExample) |
| ES (1) | ES2489475T3 (enExample) |
| HR (1) | HRP20140729T1 (enExample) |
| IL (1) | IL218293A (enExample) |
| MX (1) | MX2012003084A (enExample) |
| PL (1) | PL2500036T3 (enExample) |
| PT (1) | PT2500036E (enExample) |
| RS (1) | RS53468B (enExample) |
| SG (1) | SG184637A1 (enExample) |
| SI (1) | SI2500036T1 (enExample) |
| SM (1) | SMT201400106B (enExample) |
| ZA (1) | ZA201201992B (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9168300B2 (en) | 2013-03-14 | 2015-10-27 | Oncomed Pharmaceuticals, Inc. | MET-binding agents and uses thereof |
| TWI782930B (zh) | 2016-11-16 | 2022-11-11 | 美商再生元醫藥公司 | 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法 |
| IT201800009282A1 (it) * | 2018-10-09 | 2020-04-09 | Metis Prec Medicine Sb Srl | Nuovo agente terapeutico per il trattamento di un tumore e/o metastasi |
| CN110320365B (zh) * | 2019-07-06 | 2022-07-22 | 湖南莱拓福生物科技有限公司 | NF-κB RelA/p65蛋白位点特异性磷酸化诊断试剂盒 |
| US11896682B2 (en) | 2019-09-16 | 2024-02-13 | Regeneron Pharmaceuticals, Inc. | Radiolabeled MET binding proteins for immuno-PET imaging and methods of use thereof |
| WO2024206858A1 (en) | 2023-03-30 | 2024-10-03 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| WO2024229406A1 (en) | 2023-05-04 | 2024-11-07 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| TW202530228A (zh) | 2023-10-12 | 2025-08-01 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI310684B (en) * | 2000-03-27 | 2009-06-11 | Bristol Myers Squibb Co | Synergistic pharmaceutical kits for treating cancer |
| BRPI0407446A (pt) * | 2003-02-13 | 2006-01-31 | Pharmacia Corp | Anticorpos para c-met para o tratamento de cânceres |
| EP1648998B1 (en) * | 2003-07-18 | 2014-10-01 | Amgen Inc. | Specific binding agents to hepatocyte growth factor |
| HN2004000285A (es) * | 2003-08-04 | 2006-04-27 | Pfizer Prod Inc | ANTICUERPOS DIRIGIDOS A c-MET |
| EP1981981B1 (en) * | 2006-02-06 | 2011-06-29 | Metheresis Translational Research SA | Anti-met monoclonal antibody, fragments and vectors thereof, for the treatment of tumors and corresponding products |
| EP2019116A1 (en) * | 2007-07-26 | 2009-01-28 | Helmholtz-Zentrum für Infektionsforschung GmbH | Inhibitor of the met-receptor and its use |
-
2011
- 2011-03-18 DK DK11158861.2T patent/DK2500036T3/da active
- 2011-03-18 EP EP11158861.2A patent/EP2500036B1/en active Active
- 2011-03-18 SI SI201130217T patent/SI2500036T1/sl unknown
- 2011-03-18 PL PL11158861T patent/PL2500036T3/pl unknown
- 2011-03-18 PT PT111588612T patent/PT2500036E/pt unknown
- 2011-03-18 RS RS20140404A patent/RS53468B/sr unknown
- 2011-03-18 ES ES11158861.2T patent/ES2489475T3/es active Active
-
2012
- 2012-02-22 SG SG2012012514A patent/SG184637A1/en unknown
- 2012-02-23 IL IL218293A patent/IL218293A/en active IP Right Grant
- 2012-02-24 JP JP2012039193A patent/JP5671487B2/ja active Active
- 2012-03-01 CA CA2769991A patent/CA2769991C/en active Active
- 2012-03-02 AU AU2012201303A patent/AU2012201303B2/en active Active
- 2012-03-13 MX MX2012003084A patent/MX2012003084A/es active IP Right Grant
- 2012-03-13 KR KR1020120025311A patent/KR101540838B1/ko active Active
- 2012-03-16 ZA ZA2012/01992A patent/ZA201201992B/en unknown
- 2012-03-16 EA EA201200329A patent/EA028590B1/ru not_active IP Right Cessation
- 2012-03-16 CN CN2012100803665A patent/CN102688491A/zh active Pending
- 2012-03-16 BR BR102012006063-9A patent/BR102012006063B1/pt active IP Right Grant
- 2012-03-19 US US13/423,830 patent/US20120237524A1/en not_active Abandoned
-
2014
- 2014-07-24 CY CY20141100561T patent/CY1115374T1/el unknown
- 2014-07-29 HR HRP20140729AT patent/HRP20140729T1/hr unknown
- 2014-07-31 SM SM201400106T patent/SMT201400106B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2769991C (en) | 2018-05-15 |
| CA2769991A1 (en) | 2012-09-18 |
| AU2012201303B2 (en) | 2013-11-07 |
| AU2012201303A1 (en) | 2012-10-04 |
| KR20120106582A (ko) | 2012-09-26 |
| CY1115374T1 (el) | 2017-01-04 |
| SG184637A1 (en) | 2012-10-30 |
| EA201200329A3 (ru) | 2013-01-30 |
| ES2489475T3 (es) | 2014-09-02 |
| PT2500036E (pt) | 2014-08-25 |
| IL218293A (en) | 2016-06-30 |
| HRP20140729T1 (hr) | 2014-08-29 |
| JP2012196206A (ja) | 2012-10-18 |
| PL2500036T3 (pl) | 2014-10-31 |
| EA201200329A2 (ru) | 2012-09-28 |
| IL218293A0 (en) | 2012-07-31 |
| BR102012006063A2 (pt) | 2021-11-16 |
| SMT201400106B (it) | 2014-11-10 |
| KR101540838B1 (ko) | 2015-08-06 |
| US20120237524A1 (en) | 2012-09-20 |
| HK1174539A1 (en) | 2013-06-14 |
| JP5671487B2 (ja) | 2015-02-18 |
| CN102688491A (zh) | 2012-09-26 |
| EP2500036B1 (en) | 2014-05-07 |
| MX2012003084A (es) | 2012-09-17 |
| DK2500036T3 (da) | 2014-08-04 |
| BR102012006063A8 (pt) | 2022-11-08 |
| SI2500036T1 (sl) | 2014-09-30 |
| EP2500036A1 (en) | 2012-09-19 |
| EA028590B1 (ru) | 2017-12-29 |
| BR102012006063B1 (pt) | 2023-03-07 |
| ZA201201992B (en) | 2015-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RS53468B (sr) | Inhibitori met aktivnosti za primenu u cilju povećanja efikasnosti radioterapije | |
| Li et al. | Programmed cell death‐1 (PD‐1) checkpoint blockade in combination with a mammalian target of rapamycin inhibitor restrains hepatocellular carcinoma growth induced by hepatoma cell–intrinsic PD‐1 | |
| Chen et al. | High mobility group protein B1 controls liver cancer initiation through yes‐associated protein‐dependent aerobic glycolysis | |
| Yu et al. | Potential approaches to the treatment of Ewing's sarcoma | |
| Hou et al. | N-Myc-interacting protein (NMI) negatively regulates epithelial-mesenchymal transition by inhibiting the acetylation of NF-κB/p65 | |
| CN112543809A (zh) | 包含C/EBPα saRNA的组合疗法 | |
| JP2017526670A (ja) | ネクロトーシス（ｎｅｃｒｏｐｔｏｓｉｓ）の阻害による腫瘍転移の阻止 | |
| Guo et al. | FGF19/FGFR4 signaling contributes to hepatocellular carcinoma survival and immune escape by regulating IGF2BP1-mediated expression of PD-L1 | |
| EP2723350B1 (en) | New uses of nanog inhibitors and related methods | |
| JP2025118790A (ja) | Ｆｍｒｐ及び癌治療 | |
| US20200326343A1 (en) | Gene and its expression product promoting the occurrence and development of cancer and application | |
| Zhao et al. | PPARγ and C/EBPα enable adipocyte differentiation upon inhibition of histone methyltransferase PRC2 in malignant tumors | |
| US9623109B2 (en) | Methods of killing cells and use of same in prevention and treatment of cancer | |
| Chen et al. | SNF5, a core subunit of SWI/SNF complex, regulates melanoma cancer cell growth, metastasis, and immune escape in response to matrix stiffness | |
| Li et al. | PD-1 checkpoint blockade in combination with an mTOR inhibitor restrains hepatocellular carcinoma growth induced by hepatoma cell-intrinsic PD-1 | |
| JP7057975B2 (ja) | 殺細胞効果を有するキメラ抗原受容体遺伝子改変リンパ球 | |
| CN113908280A (zh) | Trim11抑制剂和二甲双胍的组合物在治疗肝细胞癌中的应用 | |
| CN114762730A (zh) | Pcsk9在肿瘤免疫治疗、增强免疫细胞免疫效应中的应用 | |
| Shi et al. | Inhibition of PD-L1 expression in non-small cell lung cancer may reduce vasculogenic mimicry formation by inhibiting the epithelial mesenchymal transformation process | |
| HK1174539B (en) | Met inhibitors for enhancing radiotherapy efficacy | |
| CN111363034B (zh) | 一种NANOG Ser68的抗体，以及抑制剂和应用 | |
| Zhou et al. | Broad-spectrum antitumor analysis of the telomerase activity inhibitor TPCH derived from the human constitutively expressed protein LPTS/PinX1 | |
| CN121130073A (zh) | 一种增强nk细胞治疗非小细胞肺癌效果的组合物及其应用 | |
| CN120249393A (zh) | 一种基因表达载体及其体内递送的重组腺相关病毒和在癌症治疗中的应用 | |
| CN116942816A (zh) | Snip1为靶点在制备或筛选抗肿瘤药物中的应用 |